期刊文献+

草酸铂和伊立替康、氟尿嘧啶联合方案治疗晚期肠癌 被引量:3

Treatment of advanced and metastatic colorectal cancer with combined chemotherapy based on oxaliplatin,irinotecan and fluorouracil
在线阅读 下载PDF
导出
摘要 目的 :总结探讨草酸铂和伊立替康、氟尿嘧啶联合方案治疗晚期肠癌近期疗效及毒副反应。方法 :2 5例晚期肠癌 ,用草酸铂、伊立替康和氟尿嘧啶 +亚叶酸联合方案静脉应用或动脉介入 +静脉用药 ,治疗两周期评价疗效及相关症状改善 (DRSI)及毒副反应。结果 :经治疗动脉介入 +静脉用药组 15例 ,CR 1例 ,PR 9例 ,有效率 6 6 .6 %。静脉用药组 10例 ,PR 4例 ,有效率 4 0 .0 % ,两组疗效无显著差异 (P >0 .0 5 )。总有效率为 5 6 .0 %。 18例相关症状改善 ,毒副反应可耐受 ,未见严重不可逆反应。结论 :草酸铂和伊立替康和氟尿嘧啶联合方案治疗晚期肠癌复发或转移患者 ,疗效明确 ,安全有效 ,毒副作用小 ,无叠加毒性 ,可明显改善患者症状 ,提高生存质量。 Purpose:To investigate the efficacy of combined chemotherapy based on Oxaliplatin(OXA),Irinotecan(CPT-11)and fluorouracil(5-Fu),for treatment of relapse and metastatic colorectal cancer and its side-effects. Methods:25 cases of relapse and metastatic colorectal cancer by interventional arterial chemotherapy and iv drip,based on Oxaliplatin,Irinotecan and 5-Fu,CF,then after 2 cycles of treatment,the efficacy and clinical symptoms were evaluated. Results:After treatment,the terventional arterial group 1/15 achieved CR,9/15 achieved PR,the response rate was 66.7%. In the iv drip group 4/10 achieved PR,response rate was 40.0%,there was no significant difference between the two groups(P>0.05),the overall response rate was 56.0% .Symptoms(18/25) related to cancer improved and side-reactions were tolerable. Conclusions:Treatment of relapse and metastatic colorectal cancer with combined chemotherapy based on oxaliplatin,irinotecan and 5-Fu by arterial intervention and iv drip is safe and effective,with only slight side-effects. This treatment can improve the symptoms and life quality of patients.
出处 《中国癌症杂志》 CAS CSCD 2004年第4期345-347,共3页 China Oncology
关键词 复发转移性肠癌 草酸铂 伊立替康 化疗 relapse and metastasis colorectal cancer oxaliplatin irinotecan combined chemotherapy
  • 相关文献

参考文献5

  • 1Souglakos J ,Mavroudis D,kakolyris S, et al. Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracial and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase Ⅱtrial[J]. J Clin Oncol,
  • 2Raymond E, Faivre S, Woynarowski JM, et al. Oxaliplatin: mechanism of action and antineoplastic activity[J] . Semin Oncol,1998, 25(Suppl 5):4-12.
  • 3Grand TG, Dattino RM, Efficacy E, et al.Circadian optimization of irinotecan and oxaliplatin in mice with glasgow osteosarcoma [J]. Br J Cancer, 2002, 86(6):999-1005.
  • 4应江山,曹军宁,印季良,洪小南,许立功.伊立替康二线治疗14例晚期结直肠癌[J].中国癌症杂志,2002,12(3):251-253. 被引量:8
  • 5范卫君,吴沛宏,孙一,胡雯,张福君,黄金华,郭武华.乐沙定在结、直肠癌肝转移介入治疗中的应用[J].中国肿瘤临床,2001,28(12):940-941. 被引量:5

二级参考文献1

共引文献11

同被引文献25

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部